Table 3. Mean survival of patients.
| Marker | Level of expression | Mean survival (months) |
|---|---|---|
|
CC3 | ||
|
Tumour | ||
| |
Low |
53 |
| |
High |
73 |
| |
Tumour-associated stroma |
|
| |
Low |
63 |
| |
High |
79 |
| |
Tumour
vs
tumour-associated stroma |
|
| |
Low tumour/low tumour-associated stroma (0) |
43 |
| |
Low tumour/high tumour-associated stroma (1) |
71 |
| |
High tumour/low tumour-associated stroma (2) |
66 |
| |
High tumour/high tumour-associated stroma (3) |
80 |
|
MHC-II | ||
|
Tumour | ||
| |
Negative |
71 |
| |
Positive |
85 |
| |
Tumour-associated stroma |
|
| |
Negative |
69 |
| |
Positive |
75 |
|
Cleaved PARP | ||
|
Tumour | ||
| |
Low |
70 |
| |
High |
79 |
| |
Tumour-associated stroma |
|
| |
Low |
69 |
| High | 84 | |
Abbreviations: CC3=cleaved caspase-3; MHC-II=major histocompatibility class II; PARP=poly (ADP-ribose) polymerase.